One titrimetric and two spectrophotometric methods which are simple, sensitive, and economic are described for the determination of sumatriptan succinate (STS) in bulk drug and in tablet dosage form using N-bromosuccinimide (NBS) as a brominating agent. In titrimetry, aqueous solution of STS is treated with a measured excess of NBS in acetic acid medium, and after the bromination of STS is judged to be complete, the unreacted NBS is determined iodometrically (method A). Spectrophotometric methods entail addition of a known excess of NBS in acid medium followed by the determination of residual NBS by its reaction with excess iodide, and the liberated iodine ( ) is either measured at 370？nm (method B) or liberated iodine is reacted with starch followed by the measurement of the blue colored starch-iodine complex at 570？nm (method C). Titrimetric method is applicable over range 1.0–10.0？mg STS (method A), and the reaction stoichiometry is found to be 1？:？3 (STS？:？NBS). The spectrophotometric methods obey Beer’s law for concentration range 0.6–15.0？μg？mL？1 (method B) and 0.2–4.0？μg？mL？1 (method C). The calculated apparent molar absorptivity values were found to be 2.10 × 104 and 7.44 × 104？L？mol？1？cm？1, for method B and method C, respectively. 1. Introduction Triptans are a group of tryptamine-based drugs used in the acute treatment of migraine headaches. Sumatriptan succinate (Figure 1) is one among them and is structurally related to the neurotransmitter serotonin. Sumatriptan succinate (STS) is a 5-hydroxytryptamine (5-HT) receptor subtype (a member of the 5-HT 1D family) having only a week affinity for , , and 5-HT7 receptors and chemically designated as [3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulphonamide hydrogen butanedioate [1]. STS acts by selectively binding to serotonin type-1D receptors (serotonin agonist) and rapidly terminates a migraine attack while eliminating associated symptoms such as nausea, vomiting, and light and sound sensitivity [2]. Figure 1: Structure of STS. STS has official monographs in BP [1], EP [3], and USP [4] which describe liquid chromatographic methods for the assay of STS. From the literature survey, it is found that high performance liquid chromatography (HPLC) has been used for the assay of STS in human plasma [5, 6], human serum [7], rabbit plasma [8], and human plasma and urine [9] whereas liquid chromatography-mass spectrophotometry is used (LC-MS/MS) in body fluids [10] and human plasma [11]. Several methods have been reported for the determination of STS in pharmaceuticals and include
References
[1]
British Pharmacopoeia, Her Majesty's Stationery Office, vol. 2, London, UK, 1964.
European Pharmacopoeia, EDQM Council of Europe, vol. 2, Staranborg, France, 2007.
[4]
The United States Pharmacopoeia, USP Convention, INC, Twinbrook, 12th edition, 2004.
[5]
Z. Ge, E. Tessier, L. Neirinck, and Z. Zhu, “High performance liquid chromatographic method for the determination of sumatriptan with fluorescence detection in human plasma,” Journal of Chromatography B, vol. 806, no. 2, pp. 299–303, 2004.
[6]
M. Franklin, J. Odontiadis, and E. M. Clement, “Determination of sumatriptan succinate in human plasma by high-performance liquid chromatography with coulometric detection and utilization of solid-phase extraction,” Journal of Chromatography B, vol. 681, no. 2, pp. 416–420, 1996.
[7]
M. Dunne and P. Andrew, “Fully automated assay for the determination of sumatriptan in human serum using solid-phase extraction and high-performance liquid chromatography with electrochemical detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 14, no. 6, pp. 721–726, 1996.
[8]
R. Sheshala, N. Khan, and Y. Darwis, “Validated high performance liquid chromatography (HPLC) method for the determination of sumatriptan in rabbit plasma: application to pharmacokinetic study,” Journal of Pharmacy and PharmacologyNo, vol. 6, no. 2, pp. 98–107, 2012.
[9]
P. D. Andrew, H. L. Birch, and D. A. Phillpot, “Determination of sumatriptan succinate in plasma and urine by high- performance liquid chromatography with electrochemical detection,” Journal of Pharmaceutical Sciences, vol. 82, no. 1, pp. 73–76, 1993.
[10]
K. N. Cheng, M. J. Redrup, A. Barrow, and P. N. Williams, “Validation of a liquid chromatographic tandem mass spectrometric method for the determination of sumatriptan in human biological fluids,” Journal of Pharmaceutical and Biomedical Analysis, vol. 17, no. 3, pp. 399–408, 1998.
[11]
J. Oxford and M. S. Lant, “Development and validation of a liquid chromatographic-mass spectrometric assay for the determination of sumatriptan in plasma,” Journal of Chromatography, vol. 496, no. 1, pp. 137–146, 1989.
[12]
A. E. Prabahar, R. Kalaichelvi, B. Thangabalan, R. Karthikeyan, C. Prabhakar, and P. V. Kumar, “Validated spectroscopic method for estimation of sumatriptan succinate in pure and from tablet formulation,” Research Journal of Pharmacy and Technology, vol. 2, no. 3, pp. 495–497, 2009.
[13]
R. P. Gondalia and A. P. Dharamsi, “Spectrophotometric simultaneous estimation of sumatriptan succinate and naproxen sodium in tablet dosage forms,” Asian Journal of Pharmaceutical and Clinical Research, vol. 4, no. 2, pp. 31–32, 2011.
[14]
M. R. Pourmand, M. S. Azar, and M. Aghavalijamaat, “Development of validated UV spectrophotometric method for in vitro analysis of sumatriptan in pharmaceutical preparations in comparison with HPLC,” Pharmaceutical Chemistry Journal, vol. 44, no. 10, pp. 585–589, 2011.
[15]
M. Trinath, S. K. Banerjee, H. D. Teja, and C. G. Bonde, “Development and validation of spectrophotometric method for simultaneous estimation of sumatriptan and naproxen sodium in tablet dosage form,” Der Pharmacia Sinica, vol. 1, no. 1, pp. 36–41, 2010.
[16]
L. I. Bebawy, A. A. Moustafa, and N. F. Abo-Talib, “Stability-indicating methods for the determination of sumatriptan succinate,” Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 6, pp. 1123–1133, 2003.
[17]
A. B. Avadhanulu, J. S. Srinivas, and Y. Anjaneyulu, “Reverse phase HPLC and colorimetric determination of sumatriptan succinate in its drug form,” Indian Drugs, vol. 33, no. 7, pp. 334–337, 1996.
[18]
V. A. Shirsat, S. Y. Gabhe, and S. G. Deshpande, “High performance liquid chromatographic determination of sumatriptan succinate from pharmaceutical preparation,” Indian Drugs, vol. 35, no. 7, pp. 404–407, 1998.
[19]
S. Singh and R. Jain, “Stability indicating HPLC method for the determination of sumatriptan succinate in pharmaceutical preparations and its application in dissolution rate studies,” Indian Drugs, vol. 34, no. 9, pp. 527–531, 1997.
[20]
N. Badwe, N. Sharma, and N. Agarwal, “HPLC determination of sumatriptan succinate in pharmaceutical dosage forms,” Eastern Pharmacist, vol. 40, no. 475, pp. 121–122, 1997.
[21]
Y. R. Reddy, K. K. Kumar, M. R. P. Reddy, and K. Mukkanti, “Rapid simultaneous determination of sumatriptan succinate and naproxen sodium in combined tablets by validated ultra performance liquid chromatographic method,” Journal of Analytical & Bioanalytical Techniques, vol. 2, no. 3, pp. 1–6, 2011.
[22]
D. N. Tipre and P. R. Vavia, “Estimation of Sumatriptan succinate in pharmaceutical dosage form by spectrophotometric and HPTLC method,” Indian Drugs, vol. 36, no. 8, pp. 501–505, 1999.
[23]
K. D. Altria and S. D. Filbey, “Quantitative determination of sumatriptan by capillary electrophoresis,” Analytical Proceedings, vol. 30, no. 9, pp. 363–365, 1993.
[24]
K. M. Al Azzam, B. Saad, C. Y. Tat, I. Mat, and H. Y. Aboul-Enein, “Stability-indicating micellar electrokinetic chromatography method for the analysis of sumatriptan succinate in pharmaceutical formulations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 56, no. 5, pp. 937–943, 2011.
[25]
K. Sagar, J. M. Fernandez Alvarez, C. Hua, M. R. Smyth, and R. Munden, “Differential pulse voltammetric determination of sumatriptan succinate (1:1) in a tablet dosage form,” Journal of Pharmaceutical and Biomedical Analysis, vol. 10, no. 1, pp. 17–21, 1992.
[26]
S. Shahrokhian, Z. Kamalzadeh, and R.-S. Saberi, “Glassy carbon electrode modified with a bilayer of multi-walled carbon nanotube and polypyrrole doped with new coccine: application to the sensitive electrochemical determination of Sumatriptan,” Electrochimica Acta, vol. 56, no. 27, pp. 10032–10038, 2011.
[27]
M. Amiri, Z. Pakdel, A. Bezaatpour, and S. Shahrokhian, “Electrocatalytic determination of sumatriptan on the surface of carbon-paste electrode modified with a composite of cobalt/Schiff-base complex and carbon nanotube,” Bioelectrochemistry, vol. 81, no. 2, pp. 81–85, 2011.
[28]
B. Kalyanaramu and K. Raghubabu, “Visible spectrophotometric methods for the estimation of sumatriptan succinate in bulk and dosage forms,” Acta Ciencia Indica, Chemistry, vol. 37, no. 2, pp. 143–147, 2011.
[29]
B. Kalyanaramu and K. Raghubabu, “A simple visible spectrophotometric determination of sumatriptan succinate from pharmaceutical formulations,” Der Pharma Chemica, vol. 3, no. 1, pp. 223–228, 2011.
[30]
B. K. Ramu and K. Raghubabu, “A simple colorimetric determination of sumatriptan succinate from tablet dosage forms using cobalt thio cyanate,” International Journal of Pharmacy and Technology, vol. 3, no. 1, pp. 1411–1418, 2011.
[31]
B. Kalyana Ramu and K. Raghubabu, “Ion association method for the determination of sumatriptan succinate from tablet dosage forms using tropaeolin OOO,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 3, pp. 175–178, 2011.
[32]
B. Kalyanaramu, G. Rupakumari, K. Ramarao, and K. Raghubabu, “Development of new visible spectrophotometric methods for quantitative determination of sumatriptan succinate based on charge-transfer complex formation,” International Journal of Pharmacy and Pharmaceutical Science Research, vol. 1, no. 2, pp. 47–51, 2011.
[33]
A. Fathima, S. Rao, and G. Venkateshwarlu, “Quantitative determination of drugs & pharmaceuticals using p-chloranilic acid as reagent,” International Journal of ChemTech Research, vol. 4, no. 1, pp. 79–91, 2012.
[34]
B. Kalyanaramu and K. Raghubabu, “Visible spectrophotometric determination of sumatriptan succinate in tablet dosage forms using folin reagent,” International Journal of Pharmaceutical Biomedcal SciencesNo, vol. 1, no. 3, pp. 49–52, 2010.
[35]
D. N. Tipre and P. R. Vavia, “Estimation of Sumatriptan succinate in pharmaceutical dosage form by spectrophotometric and HPTLC method,” Indian Drugs, vol. 36, no. 8, pp. 501–505, 1999.
[36]
K. V. V. Satyanarayana and P. N. Rao, “Sensitive bromatometric methods for the determination of sumatriptan succinate in pharmaceutical formulations,” E-Journal of Chemistry, vol. 8, no. 1, pp. 269–275, 2011.
[37]
A. Berka, J. Vulterin, and J. Zyka, Newer Redox Titrants, Pergamon Press, New York, NY, USA, 1965.
[38]
N. K. Mathur and C. K. Narang, The Determination of Organic Compounds With N-Bromosuccinimide and Allied Reagents, Academic Press, New York, NY, USA, 1975.
[39]
K. B. Vinay, H. D. Revanasiddappa, O. Z. Devi, P. J. Ramesh, and K. Basavaiah, “Rapid titrimetric and spectrophotometric determination of ofloxacin in pharmaceuticals using N-bromosuccinimide,” Brazilian Journal of Pharmaceutical Sciences, vol. 47, no. 2, pp. 251–260, 2011.
[40]
O. Zenita and K. Basavaiah, “Utility of N-bromosuccinimide for the titrimetric and spectrophotometric determination of famotidine in pharmaceutical formulations,” International Journal of Analytical Chemistry, vol. 2011, Article ID 581372, 11 pages, 2011.
[41]
K. N. Prashanth and K. Basavaiah, “Sensitive and selective methods for the determination of rizatriptan benzoate in pharmaceuticals using N-bromosuccinimide and two dyes,” Journal of Saudi Chemical Society, vol. 2012, 2012.
[42]
R. T. Morison and R. N. Boyd, Organic Chemistry, Prentice-Hall Inc. Upper Saddle River, New Jersey, NJ, USA, 6th edition, 1992.
[43]
Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R 1), Complementary Guideline on Methodology dated 06 November 1996, incorporated in November 2005, London.
